Research And Views Archives | Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Archives... Don't Miss Anything, Ever!

Here you will find all the research and views that we post on Equitymaster. Use the tools to customize the results to suit your preference!


















Authors
 

Budget 2012-13: Impact on Pharma sector

Mar 21, 2012

This article looks at the impact of Budget on the pharmaceutical sector

Pharma: Regulatory upsides in the making?

Jul 10, 2007

With healthcare costs accounting for a sizeable chunk of the GDP in both the developed and developing nations, little wonder then that governments across the world are under pressure to reduce these costs. For Indian pharma companies the competition has been intense in both the domestic and the global pharma market and a host of regulatory changes in recent times (especially in the European generics market) have been weighing heavy on companies having a presence in this region. In this article,

Pharma: Signs of revival...

May 8, 2006

The March 2006 quarter has seen robust performances by Indian pharma companies, both in the domestic and exports markets. In this write-up, we shall analyse the performance of the Indian pharma companies under our coverage and see what lies in store for them in the future. We have not included companies such as Dr. Reddy's and Sun Pharma as they are yet to declare their results.

Pharma: Partners in growth?

Apr 17, 2006

While pharma companies seem to have left the demons of the past year well behind them, challenges still abound in the global generics arena, in the domestic market and even in discovery research. And this is due to changing fundamentals and business dynamics of the sector. One is the introduction of the product patent law. The other is the increased competition and brutal price erosion in the generics market.

Pharma: Will ghosts of 2005 return?

Dec 27, 2005

The Sensex in the past one year scaled new peaks and touched the coveted 9,000 mark. The BSE Healthcare index, in the meanwhile, failed to set the pulse racing. Nothing highlights this fact more clearly than the following statistic - In the past one year, while the Sensex zoomed and notched up 44% gains, the healthcare index has significantly under performed the benchmark managing to garner a mere 2% gains!

Ranbaxy VS Dr. Reddy's: Clash of the titans!

Oct 5, 2005

Domestic pharma heavyweights, Ranbaxy and Dr.Reddy's have been the pioneers in establishing a global presence and moving ahead of competition in new drug discovery in the domestic pharma industry. While both the companies have similar business models (in respect of focus on generics and new drug discovery), we take a look at how these companies compare against each other on certain parameters.

Pharma: New drug wonders!

Sep 21, 2005

Until January 2005, since India had recognized process patents, it resulted in domestic pharma companies becoming an expert in 'reverse engineering’ of products. However, a major development took place in the Indian pharmaceutical market, when the product patent law was introduced with effect from January 1, 2005. This means that domestic majors will have to focus on new drug discovery research in the long term if they want to benchmark themselves against the global pharma majors. In this articl

Wockhardt: Europe led 2004

Feb 10, 2005

Domestic pharma company, Wockhardt, recently declared its December quarter as well as full year numbers. In 4QCY04, the company's consolidated revenues clocked a buoyant 21% growth led by strong performance in Europe and rest of the world. Its bottomline growth was equally buoyant at 26% YoY. The company ended the full year with over 31% revenue and nearly 50% bottomline growth.

Lupin: Base effect mars performance

Nov 19, 2004

Domestic pharma company, Lupin, announced dismal results in 2QFY05. While the topline has declined by 8.5%, the operating profit has declined at a faster rate of 60% YoY. The net profit however, has increased by about 20 times, which does not show the true picture, as this rise in profit is on back of some extraordinary expenses last year.

Nicholas Piramal: Roche blues for now

Oct 25, 2004

Domestic pharma major, Nicholas Piramal, has declared its 2QFY05 and 1HFY05 results. In the quarter, the topline of the company has grown by 2%, while the net profit increased by 7% led by expansion of operating margin, which stood at 21.9%. In the first half of current financial year, the net profit has increased by 25.1%, while topline is down marginally.

Wockhardt: Sustainability is the key

Oct 21, 2004

Domestic pharma company, Wockhardt, has declared its 3QCY04 and 9mCY04 results. In 3QCY04, the company's topline grew by 11.3% led by decent show of its European operations. The bottomline grew by 13.6%, basically led by expansion of operating margins by nearly 4%.

Biocon: Clinical performance

Oct 20, 2004

Biocon, a leading biopharmaceutical company, has declared its 2QFY05 results, reporting strong topline and bottomline growth. The topline of the company grew by 24%, while net profit witnessed a growth of 54%. However, the operating margins of the company saw a 70 basis points decline.

Biocon: What's in the genes?

Sep 1, 2004

Biocon is India's largest Biotechnology company with presence in biopharmaceuticals, enzymes, custom research and clinical research. Biocon evolved from being an enzyme producer in to a biopharmaceuticals by leveraging on its fermentation strength. The company was one of the first few Indian companies that seized the opportunity that was there in the bio-pharmaceutical space. Even though it is currently focused on biopharma products; it is still the largest enzymes producer in the country.

Biocon: Precursor to the research report

Jul 12, 2004

Biocon is India's largest Biotechnology company with presence in biopharmaceuticals, enzymes, custom research and clinical research. It is a leading player in supply of simvastatin (a bulk drug) in the European markets (39% of sales). Let us take a review of the company.

Biocon: Statins driving growth…

May 24, 2004

India's largest biopharmaceuticals company, Biocon, declared its maiden quarterly and annual results. Since the comparative figures for 4QFY04 are not available, we will focus on the yearly comparison. Total sales of the company has increased by 94% to Rs 5.5 bn while the net profit has risen by 219% to Rs 1.4 bn. Operating profit margin stood at 34% compared to 29%, which is due to better economies of scale. The net profit margin stood at 28% due to lower interest outgo and higher operating mar


Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

MARKET STATS